Cost-Effectiveness of Adjuvant Osimertinib With and Without Chemotherapy for Surgically Resected NSCLC
Adjuvant osimertinib alone is more cost-effective than combination therapy, but only if the willingness-to-pay is high. A reduction in the price of osimertinib would improve its cost-effectiveness profile.
Authors
- Angelos Vasilopoulos
- Janelle W. Coughlin (ORCID: https://orcid.org/0000-0001-7924-5892)
- K. Robert Shen (ORCID: https://orcid.org/0000-0001-9605-1635)
- Zaid M. Abdelsattar (ORCID: https://orcid.org/0000-0001-8025-0410)
- Ayham M. Odeh (ORCID: https://orcid.org/0009-0007-0304-7655)
- A. G. Pohlman
Institutions
- Loyola University Medical Center (US)
- Mayo Clinic (US)
- Loyola University Chicago (US)
- Edward Hines, Jr. VA Hospital (US)
- University of Illinois Chicago (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100833
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00